10/10
05:50 am
grts
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
High
Report
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
10/3
05:57 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at B. Riley from a "strong-buy" rating to a "hold" rating.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at B. Riley from a "strong-buy" rating to a "hold" rating.
10/3
05:57 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
10/2
09:13 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.00 price target on the stock, down previously from $3.00.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.00 price target on the stock, down previously from $3.00.
10/1
02:02 pm
grts
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock, down previously from $4.00.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock, down previously from $4.00.
10/1
07:36 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
High
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
9/30
04:05 pm
grts
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
High
Report
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer